Abstract submission is NOW OPEN through Jan. 31, 2025! Send us your research for possible presentation at the 28th Annual Meeting!
SalioGen CEO Jason Cole joins host Emily Walsh Martin, PhD to explore the company's cutting-edge transposase-based gene insertion technology presented at the ASGCT Annual Meeting.
In this Very Special Episode, Emily Walsh Martin, PhD explores the cutting-edge transposase-based technology presented by SalioGen at the ASGCT Annual Meeting in which they achieved gene insertion without double-strand breaks. Join us as Jason Cole, CEO at SalioGen, takes us on a captivating journey through the company's groundbreaking work, including their initial data in Stargardt disease using LNP delivery to photoreceptors.
But that's not all! Discover Jason's unconventional path from small molecules to genetic medicines and gain insights into the strategic value of using a target product profile to guide development decisions.
Finally, we delve into the transformative potential of genetic medicine, bridging the gap from bench to bedside to payer-to-patient access.
And before we dive in, a quick reminder: The ASGCT Policy Summit (Sept 23-24 in DC or online) is an absolute must for R&D scientists, analytical experts, clinical researchers, and program managers seeking a comprehensive understanding of genetic medicine development. Don't miss this crucial conversation between regulators, payors, patients, caregivers, and developers.
ASGCT.org/PolicySummit
Music by: https://www.steven-obrien.net/ -------------------------- Bright New Morning - Steven O'Brien
(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)
November 19-20, 2024 | Chicago, IL
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico